Jubilant Organosys has announced that its Bangalore-based subsidiary, Jubilant Biosys has entered into a discovery and development collaboration with Endo Pharmaceuticals.
Under the terms of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.
Endo will own any compounds developed under the collaboration, and will be responsible for worldwide commercialization.
Under an initial three-year agreement, Jubilant will receive research funding and success-based development milestones from Endo, as well as royalties on the successful commercialization of the compounds developed.
Dr. Ivan Gergel, Executive Vice President of Research & Development, Endo Pharmaceuticals, said: We are excited about this opportunity with Jubilant. We look forward to our collaboration with the goal of bringing new therapies and healthcare solutions to patients.